AAAAAA
Results:
1-18
|
Results: 18
Authors:
Verschraegen, CF
Benjapibal, M
Supakarapongkul, W
Levy, LB
Ross, M
Atkinson, EN
Bodurka-Bevers, D
Kavanagh, JJ
Kudelka, AP
Legha, SS
Citation: Cf. Verschraegen et al., Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later, INT J GYN C, 11(5), 2001, pp. 359-364
Authors:
Azevedo, P
Verschraegen, CF
Kavanagh, JJ
Kudelka, AP
Freedman, RS
Lu, K
Deavers, MT
Citation: P. Azevedo et al., Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report, EUR J GYN O, 22(5), 2001, pp. 319-321
Authors:
Zavadova, E
Savary, CA
Templin, S
Verschraegen, CF
Freedman, RS
Citation: E. Zavadova et al., Maturation of dendritic cells from ovarian cancer patients, CANC CHEMOT, 48(4), 2001, pp. 289-296
Authors:
Verschraegen, CF
Kavanagh, JJ
Loyer, E
Bodurka-Bevers, D
Kudelka, AP
Hu, W
Vincent, M
Nelson, T
Levenback, C
Citation: Cf. Verschraegen et al., Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix, CANCER, 92(9), 2001, pp. 2327-2333
Authors:
Moon, C
Verschraegen, CF
Bevers, M
Freedman, R
Kudelka, AP
Kavanagh, JJ
Citation: C. Moon et al., Use of docetaxel (Taxotere (R)) in patients with paclitaxel (Taxol (R)) hypersensitivity, ANTI-CANC D, 11(7), 2000, pp. 565-568
Authors:
Verschraegen, CF
Sittisomwong, T
Kudelka, AP
Guedes, ED
Steger, M
Nelson-Taylor, T
Vincent, M
Rogers, R
Atkinson, EN
Kavanagh, JJ
Citation: Cf. Verschraegen et al., Docetaxel for patients with paclitaxel-resistant mullerian carcinoma, J CL ONCOL, 18(14), 2000, pp. 2733-2739
Authors:
Sittisomwong, T
Suneja, A
Kudelka, AP
Verschraegen, CF
Kavanagh, JJ
Citation: T. Sittisomwong et al., Estrogen replacement therapy and ovarian cancer, EUR J GYN O, 21(4), 2000, pp. 348-354
Authors:
Verstovsek, S
Verschraegen, CF
Edwards, CL
Malpica, A
Kavanagh, JJ
Ross, MI
Strom, EA
Jhingran, A
Theriault, RL
Kudelka, AP
Citation: S. Verstovsek et al., Synchronous primary cancers of the breast and cervix: Planning multidisciplinary primary treatment, AM J CL ONC, 23(1), 2000, pp. 99-103
Authors:
Hu, W
McCrea, PD
Deavers, M
Kavanagh, JJ
Kudelka, AP
Verschraegen, CF
Citation: W. Hu et al., Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovariantumors, CLIN EXP M, 18(1), 2000, pp. 83-88
Authors:
Hu, W
Wu, WG
Nash, MA
Freedman, RS
Kavanagh, JJ
Verschraegen, CF
Citation: W. Hu et al., Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancercell lines, ANTICANC R, 20(2A), 2000, pp. 729-733
Authors:
Vadhan-Raj, S
Verschraegen, CF
Bueso-Ramos, C
Broxmeyer, HE
Kudelka, AP
Freedman, RS
Edwards, CL
Gershenson, D
Jones, D
Ashby, M
Kavanagh, JJ
Citation: S. Vadhan-raj et al., Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer, ANN INT MED, 132(5), 2000, pp. 364-368
Authors:
Rosenblum, MG
Verschraegen, CF
Murray, JL
Kudelka, AP
Gano, J
Cheung, L
Kavanagh, JJ
Citation: Mg. Rosenblum et al., Phase I study of Y-90-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity, CLIN CANC R, 5(5), 1999, pp. 953-961
Authors:
Kudelka, AP
Verschraegen, CF
Shen, Y
De Leon, CG
Edwards, CL
Freedman, RS
Forman, A
Gibbs, HR
Mante, R
Hord, M
Canetta, R
Krakoff, I
Kavanagh, JJ
Citation: Ap. Kudelka et al., Long-term results and pharmacokinetics of high-dose paclitaxel in patientswith refractory epithelial ovarian carcinoma, INT J GYN C, 9(1), 1999, pp. 44-53
Authors:
Verschraegen, CF
Matei, C
Loyer, E
Malpica, A
Tornos, C
Kudelka, AP
Kavanagh, JJ
Citation: Cf. Verschraegen et al., Octreotide induced remission of a refractory small cell carcinoma of the endometrium, INT J GYN C, 9(1), 1999, pp. 80-85
Authors:
Verschraegen, CF
Gupta, F
Loyer, E
Kavanagh, JJ
Kudelka, AP
Freedman, RS
Edwards, CL
Harris, N
Steger, M
Steltz, V
Giovanella, BC
Stehlin, JS
Citation: Cf. Verschraegen et al., A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer, ANTI-CANC D, 10(4), 1999, pp. 375-383
Authors:
Verschraegen, CF
Edwards, CL
Fox, H
Citation: Cf. Verschraegen et al., Present knowledge of gynecologic sarcoma management, HEMAT ONCOL, 13(1), 1999, pp. 211
Authors:
Melichar, B
Ferrandina, G
Verschraegen, CF
Loercher, A
Abbruzzese, JL
Freedman, RS
Citation: B. Melichar et al., Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines, CLIN CANC R, 4(12), 1998, pp. 3069-3076
Authors:
Verschraegen, CF
Kudelka, AP
Loyer, E
Edwards, CL
Freedman, RS
Kavanagh, JJ
Citation: Cf. Verschraegen et al., A phase II trial of high-dose hydroxyurea administered parenterally in patients with epithelial ovarian carcinoma refractory to platinum, INT J GYN C, 8(6), 1998, pp. 494-498
Risultati:
1-18
|